Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01189747
Other study ID # 191622-098
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 1, 2010
Est. completion date July 1, 2011

Study information

Verified date April 2019
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).


Recruitment information / eligibility

Status Completed
Enrollment 446
Est. completion date July 1, 2011
Est. primary completion date April 1, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Moderate to severe Crow's Feet Lines

- Have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses OK)

Exclusion Criteria:

- Current or previous botulinum toxin treatment of any serotype

- Facial laser or light treatment, microdermabrasion or superficial peels within 3 months

- Oral retinoid therapy within 1 year

- Prior facial cosmetic surgery (eg, periorbital surgery, facial lift, brow lift, eye lift, or eyebrow surgery)

- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
onabotulinumtoxinA
24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
Drug:
normal saline
Injected into bilateral Crow's Feet Line areas on Day 1

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  United Kingdom, 

References & Publications (1)

Carruthers A, Bruce S, de Coninck A, Connolly S, Cox SE, Davis PG, Campo A, Lei X, Somogyi C, Lee E, McLean H, Beddingfield F. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial. Dermatol Surg. 2014 Nov;40(11):1181-90. doi: 10.1097/DSS.0000000000000128. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile The composite facial wrinkle scale assessment is based on both the Investigator and Subject Facial Wrinkle scales at Day 30. The Investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe and the patient assessed the severity of their Crow's Feet Lines at maximum smile using the same 4-point Facial Wrinkle Scale. A responder is defined as a participant with a = 2-grade improvement from Baseline. Baseline, Day 30
Secondary Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator's Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines The Investigator assessed the severity of the patient's Crow's Feet lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a score of none or mild at Day 30 is reported. Day 30
Secondary Percentage of Participants With a = 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Maximum Smile The Investigator assessed the severity of the patient's Crow's Feet Lines at maximum smile using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a = 1-grade improvement from Baseline at Day 30 is reported. Baseline, Day 30
Secondary Percentage of Participants With a = 1-Grade Improvement From Baseline by Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet Lines at Rest The Investigator assessed the severity of the patient's Crow's Feet Lines at rest using the 4-point Facial Wrinkle Scale: 0=none, 1=mild, 2=moderate or 3=severe. The percentage of participants with a = 1-grade improvement from Baseline at Day 30 is reported. Baseline, Day 30
Secondary Subject Global Assessment of Change in Crow's Feet Lines (SGA-CFL) Score Patients rated the change in their Crow's Feet Lines using the SGA-CFL 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse or 7=very much worse at Day 30. Lower scores indicate improvement. Day 30
Secondary Percentage of Participants Who Judged Themselves in a Younger Self-Perception of Age Category Than at Baseline Participants were considered to judge themselves younger if the category change was from "look my current age" at Baseline to "look younger" at Day 30 or from "look older" at Baseline to "look my current age/younger" at Day 30. Baseline, Day 30
Secondary Percentage of Participants With a = 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 2 at Day 30 The percentage of FLO-11 Item #2 responders, defined as participants with a = 2-point improvement in FLO-11 score from Baseline for FLO-11 Question #2: "When I look in the mirror, my facial lines make me look older than I want to look." The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). Baseline, Day 30
Secondary Percentage of Participants With a = 2-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 5 at Day 30 The percentage of FLO-11 Item #5 responders, defined as participants with a = 2-point improvement in FLO-11 score from Baseline for FLO-11 Question #5: "My facial lines make me look less attractive than I want to look." The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). Baseline, Day 30
Secondary Percentage of Participants With a = 3-point Improvement From Baseline for Facial Line Outcomes Questionnaire (FLO-11) Item 8 at Day 30 The percentage of FLO-11 Item #8 responders, defined as participants with a = 3-point improvement in FLO-11 score from baseline for FLO-11 Question #8: "My facial lines make me look tired" The FLO-11 questionnaire is comprised of 11 items that assess the subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on an 11-point scale (0=not at all, 5=somewhat, 10=very much). Baseline, Day 30
See also
  Status Clinical Trial Phase
Completed NCT02248844 - Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea
Completed NCT02195687 - BOTOX® in the Treatment of Crow's Feet Lines in China Phase 3
Completed NCT01189760 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Recruiting NCT04081402 - A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines Phase 3
Completed NCT01224015 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT02176356 - Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) Phase 4
Not yet recruiting NCT06402058 - A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement N/A
Completed NCT06376838 - To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet N/A
Not yet recruiting NCT03184363 - Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study) Phase 3
Completed NCT01797081 - BOTOX® in the Treatment of Crow's Feet Lines in Japan Phase 3
Completed NCT03408236 - Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines Phase 3
Completed NCT01797094 - BOTOX® in the Treatment of Upper Facial Lines in Japan Phase 3
Completed NCT03317574 - MEDITOXIN® in Treatment of Crow's Feet Line Phase 3